Table 1.
Subject characteristics at baseline. Data is presented as means ± standard deviation. No significant differences between groups were found at baseline (p > 0.05).
| Placebo | 50 mg | 200 mg | |
|---|---|---|---|
| Age [years] | |||
| Women (n = 11/10/11) | 20.8 ± 1.5 | 21.5 ± 3.0 | 21.5 ± 2.7 |
| Men (n = 10/10/11) | 20.8 ± 2.1 | 21.3 ± 1.8 | 21.6 ± 1.9 |
| Total (n = 21/20/22) | 20.8 ± 1.8 | 21.4 ± 2.4 | 21.6 ± 2.3 |
| Height [cm] | |||
| Women (n = 11/10/11) | 165.1 ± 5.3 | 167.6 ± 5.5 | 162.6 ± 7.8 |
| Men (n = 10/10/11) | 176.6 ± 6.4 | 178.8 ± 8.8 | 175.9 ± 5.0 |
| Total (n = 21/20/22) | 170.6 ± 8.2 | 173.2 ± 9.2 | 169.3 ± 9.4 |
| Weight [kg] | |||
| Women (n = 11/10/11) | 62.2 ± 6.0 | 61.6 ± 10.2 | 58.2 ± 8.6 |
| Men (n = 10/10/11) | 78.2 ± 9.9 | 82.8 ± 11.5 | 78.2 ± 11.6 |
| Total (n = 21/20/22) | 69.8 ± 11.3 | 72.2 ± 15.2 | 68.2 ± 14.3 |
| Body Mass Index (kg/m2) | |||
| Women (n = 11/10/11) | 22.8 ± 1.8 | 21.9 ± 3.2 | 21.9 ± 1.9 |
| Men (n = 10/10/11) | 25.1 ± 3.0 | 25.9 ± 2.6 | 25.2 ± 3.3 |
| Total (n = 21/20/22) | 23.9 ± 2.6 | 23.9 ± 3.5 | 23.6 ± 3.1 |
| Maximum Aerobic Capacity [VO2mMax in mL/kg/min] | |||
| Women (n = 11/10/11) | 39.2 ± 4.9 | 39.4 ± 4.7 | 40.9 ± 7.7 |
| Men (n = 10/10/11) | 44.4 ± 6.0 | 47.4 ± 7.4 | 46.3 ± 6.0 |
| Total (n = 21/20/22) | 41.6 ± 6.0 | 43.2 ± 7.2 | 43.6 ± 7.3 |
| Race | |||
| White | 16 (10F, 6M) | 15 (7F, 8M) | 19 (10F, 9M) |
| Asian | 3 (2 F, 1M) | 2 (1F, 1M) | 1 (1M) |
| African-American | 1 (1M) | 1 (1M) | - |
| Latino | 1 (1M) | 2 (2F) | 2 (1F, 1M) |